Aiforia H2’25: Green shoots on the clinical side

Aiforia’s H2 revenue growth originated in Europe, where the company has successfully promoted the adoption of clinical models. The digital pathology market has developed more slowly than expected, and the investment's risk profile remains high. Analyst Antti Siltanen summarizes.